Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Clinical Medicine School of Nanjing Medical University, Medicine School of Tongji University, Shanghai, 200072, China.
Department of Endocrinology and Metabolism, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Lipids Health Dis. 2022 Jan 16;21(1):10. doi: 10.1186/s12944-022-01622-0.
Lipocalin-2 (LCN2) has a critical effect on obesity as well as its associated comorbidities. The present study focused on analyzing serum LCN2 levels of obese patients with nonalcoholic fatty liver disease (NAFLD) and on determining relationship of hepatic steatosis improvement with LCN2 levels after laparoscopic sleeve gastrectomy (LSG).
This work enrolled ninety patients with obesity and NAFLD. Twenty-three of them underwent LSG. Anthropometric and biochemical parameters and serum LCN2 levels were determined at baseline and those at 6-month post-LSG. Controlled attenuation parameter (CAP) measured by FibroScan was adopted for evaluating hepatic steatosis.
Among severe obesity patients, serum LCN2 levels were significantly increased (111.59 ± 51.16 ng/mL vs. 92.68 ± 32.68 ng/mL, P = 0.035). The CAP value was higher indicating higher liver fat content (360.51 ± 45.14 dB/m vs. 340.78 ± 45.02 dB/m, P = 0.044). With regard to surgical patients, liver function, glucose, and lipid levels were significantly improved after surgery. Serum LCN2 levels significantly decreased (119.74 ± 36.15 ng/mL vs. 87.38 ± 51.65 ng/mL, P = 0.001). Decreased CAP indicated a significant decrease in liver fat content (358.48 ± 46.13 dB/m vs. 260.83 ± 69.64 dB/m, P < 0.001). The decrease in LCN2 levels was significantly related to the reduced hepatic fat content and improvement in steatosis grade after adjusting for gender, age, and BMI decrease.
Serum LCN2 levels are related to obesity and NAFLD. The decreased serum LCN2 levels could be an indicator of hepatic steatosis improvement.
脂联素-2（LCN2）对肥胖及其相关合并症有重要影响。本研究重点分析了非酒精性脂肪性肝病（NAFLD）肥胖患者的血清 LCN2 水平，并确定了腹腔镜袖状胃切除术（LSG）后 LCN2 水平与肝脂肪变性改善的关系。
本研究纳入了 90 例肥胖合并 NAFLD 的患者。其中 23 例患者接受了 LSG。在基线和 LSG 术后 6 个月时，测定了患者的人体测量学和生化参数以及血清 LCN2 水平。采用 FibroScan 检测受控衰减参数（CAP）评估肝脂肪变性。
在重度肥胖患者中，血清 LCN2 水平显著升高（111.59 ± 51.16 ng/mL 比 92.68 ± 32.68 ng/mL，P = 0.035）。CAP 值越高，提示肝内脂肪含量越高（360.51 ± 45.14 dB/m 比 340.78 ± 45.02 dB/m，P = 0.044）。对于手术患者，术后肝功能、血糖和血脂水平均显著改善。血清 LCN2 水平显著下降（119.74 ± 36.15 ng/mL 比 87.38 ± 51.65 ng/mL，P = 0.001）。CAP 值降低提示肝内脂肪含量显著减少（358.48 ± 46.13 dB/m 比 260.83 ± 69.64 dB/m，P < 0.001）。调整性别、年龄和 BMI 下降后，LCN2 水平的下降与肝脂肪含量的减少和脂肪变性程度的改善显著相关。
血清 LCN2 水平与肥胖和 NAFLD 相关。血清 LCN2 水平降低可能是肝脂肪变性改善的一个指标。
